• Explore /
  • Poster
  • / Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Abstract Video & Slides Poster

Authors

null

Johannes Düll

Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany

Johannes Düll , Kami J. Maddocks , Eva Gonzalez-Barca , Wojciech Jurczak , Anna Marina Liberati , Aleš Obr , Gianluca Gaidano , Pau Abrisqueta , Marc André , Martin H. Dreyling , Tobias Menne , Maren Dirnberger-Hertweck , Johannes Weirather , Sumeet Vijay Ambarkhane , Gilles A. Salles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02399085

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7513)

DOI

10.1200/JCO.2021.39.15_suppl.7513

Abstract #

7513

Abstract Disclosures

Similar Posters

First Author: Tongyu Lin

First Author: Jie Xu

First Author: Cyrille Touzeau

First Author: Catherine S. Magid Diefenbach